|
Protocol Number:
99-H-0046
- Title:
Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T-Cell Add-Back for Hematological Malignancies - Role of Cyclosporine
- Number:
99-H-0046
- Summary:
Cancers of the blood, sometimes referred to as hematologic malignancies, are disorders of bone marrow cells that lead to the failure of the normal function of bone marrow and the uncontrolled growth of cancerous cells in the bone marrow. These cancerous cells can spill over into the bloodstream and affect other organs causing widespread symptoms. The disease is life threatening because it blocks the normal function of the marrow, which is to produce red cells (preventing anemia), white cells (preventing infection), and platelets (preventing progression).
Bone marrow transplants are a potential form of therapy for patients with hematologic malignancies. However, BMT is a complicated procedure and can be associated with dangerous side effects.
In this study researchers are attempting to find ways to reduce the complications of BMT, so that it would be possible to use it more safely and can be offered more patients. In order to do this, researchers are developing new techniques to make BMT safer. It requires making small changes to the standard procedure, which may improve the outcome.
The experimental procedures researchers are evaluating are:
1. T-cell depleted peripheral blood progenitor cell (PBPC) transplantation
2. Cyclosporine given immediately after the transplant
3. Add-back of donor lymphocytes
Patients undergoing these experimental techniques must be monitored closely to see if any benefit or harmful effects will occur. Information gathered from this study can be used to develop further research studies and potential new therapies for hematologic malignancies.
- Sponsoring Institute:
-
National Heart, Lung and Blood Institute (NHLBI)
- Recruitment Detail
- Type:
Completed Study; data analyses ongoing
- Gender:
Male & Female
- Referral Letter Required:
No
- Population Exclusion(s):
None
- Eligibility Criteria:
This study is not currently recruiting new subjects. If you have questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
- Special Instructions:
Currently Not Provided
- Keyword(s):
-
Peripheral Blood Stem Cells
-
Cyclosporine
-
Cyclosphosphamide
-
Whole Body Irradiation
-
Donor Apheresis
-
Leukemic Relapse
-
Graft vs. Host Disease
-
Graft-Versus-Leukemia
-
Graft-Versus-Myeloma
- Recruitment Keyword(s):
-
Chronic Myelogenous Leukemia
-
Acute Lymphoblastic Leukemia
-
Acute Myelogenous Leukemia
-
Myelodysplastic Syndromes
-
Multiple Myeloma
-
Chronic Lymphocytic Leukemia
-
Non-Hodgkin's Lymphoma
- Condition(s):
-
Chronic Lymphocytic Leukemia
-
Graft vs Host Disease
-
Hematologic Neoplasm
-
Multiple Myeloma
-
Myelodysplastic Syndrome
- Investigational Drug(s):
- None
- Investigational Device(s):
- None
- Interventions:
-
Device: Isolex 300i plus MoAbs
- Supporting Site:
-
National Heart, Lung and Blood Institute
- Contact(s):
-
This study is not currently recruiting new subjects. If you have questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
- Citation(s):
-
Primary transpantation of allogeneic peripheral blood progenitor cells mobilized by Filgastrim (G-CSF)
-
Transplantation of allogeneic perpheral blood stem cells mobilized by recombinant human granulocyte-stimulating factor
-
Peripheral blood progenitor cell transplantion: A replacement for marrow auto- or allografting
If you have:
Search The Studies | Help | Questions | Clinical Center Home | NIH Home
National Institutes of Health Clinical Center
Bethesda, Maryland 20892. Last update: 01/17/2009
|
|